impact factor, citescore
logo
In press
In Press
Recent issue
Recent issue
Recent Supplement
Recent supplement
archives
Archives
articles free
Free to view
Search
Search
 

Reviews

 

Usefulness of six-minute walk test in systemic sclerosis

1, 2, 3, 4, 5, 6, 7, 8, 9

 

  1. Respiratory Unit, Centre for Sleep and Respiratory Disorders, Luigi Sacco University Hospital, Milan, Italy. rizzi.maurizio@asst-fbf-sacco.it
  2. Department of Biomedical Sciences, Luigi Sacco Hospital, Milan, Italy.
  3. Department of Biomedical Sciences, Luigi Sacco Hospital, Milan, Italy.
  4. Respiratory Unit, Centre for Sleep and Respiratory Disorders, Luigi Sacco University Hospital, Milan, Italy.
  5. Respiratory Unit, Centre for Sleep and Respiratory Disorders, Luigi Sacco University Hospital, Milan, Italy.
  6. Respiratory Unit, Centre for Sleep and Respiratory Disorders, Luigi Sacco University Hospital, Milan, Italy.
  7. Respiratory Unit, Centre for Sleep and Respiratory Disorders, Luigi Sacco University Hospital, Milan, Italy.
  8. Rheumatology Unit, Luigi Sacco University Hospital, Milan, Italy.
  9. Rheumatology Unit, University of Messina, Italy.

CER11105
2018 Vol.36, N°4 ,Suppl.113
PI 0161, PF 0167
Reviews

Free to view
(click on article PDF icon to read the article)

PMID: 30277863 [PubMed]

Received: 14/01/2018
Accepted : 14/02/2018
In Press: 07/09/2018
Published: 30/09/2018

Abstract

The 6-minute walk test (6MWT) is a standardised, feasible and reliable measure of sub-maximal exercise capacity that has never been fully validated in systemic sclerosis (SSc). A variety of data suggest that many non-pulmonary aspects of SSc contribute to the test results, thus blunting the ability of the 6MWT to measure changes in lung function. Sources of variability are a training effect, technician experience, subject encouragement, medication, other activities on day of testing, deconditioning and the effects of musculoskeletal conditions and pain. Another cause of variability is the anatomical site the probe is attached to: a forehead probe is preferable to a finger or earlobe sensor. The indiscriminate use of the 6MWT for all SSc patients is not useful. It should be used in patients with pulmonary involvement, combined with diffusion capacity of the lung for carbon monoxide (DLCO) and its components (membrane diffusion and capillary volume) or the Sclerodermia Health Assessment Questionnaire Disability Index. The use of these combined parameters may indicate the onset of pulmonary hypertension. Recent studies suggest two alternatives to the 6MWT: maximal cardiopulmonary exercise testing and DLCO testing during effort. However, their use must still be validated.

Rheumatology Article